Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp at Evercore ISI HealthCONx Virtual Conference Transcript

Nov 30, 2021 / 07:15PM GMT
Release Date Price: $67.72 (-3.77%)
Maneka Mirchandaney
Evercore ISI Institutional Equities, Research Division - Analyst

Awesome. Hi, everyone. This is Maneka Mirchandaney from the Evercore ISI biotech team. Very pleased to be here with Incyte at a pretty important time for the company with what looks to be a pretty strong start for Opzelura.

From the team, we've got Christiana Stamoulis, who is EVP and CFO; Steven Stein, who is EVP and CMO; and Christine Chiou, who is the Head of IR. Thank you all for joining.

And I really wanted to start with Opzelura since that's clearly been the big area of focus this year. I think we're all kind of watching the IQVIA scripts that seems to be off to a good start for atopic derm. But maybe you can talk a little bit about the initial launch trajectory, how that's going, and some of the early feedback that you're hearing from physicians.

Questions & Answers

Christiana Stamoulis
Incyte Corporation - Executive VP & CFO

Sure. So the launch is going very well. It's a very strong launch, and I'm sure people are looking at the IQVIA

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot